CAR-T & Cellular Therapy
The Lymphoma Sessions: highlights from ASH 2020
Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for…
Date: 17th March 2021
VJSession: EBMT/EHA CAR-T Nursing Session
The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European…
Date: 23rd February 2021
The Myeloma Sessions: key updates from ASH 2020
Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm,…
Date: 22nd February 2021
The AML Sessions: highlights from ASH 2020
Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm…
Date: 16th February 2021
Advances in CAR T-cell therapies for lymphoma from ASH 2020
Lymphoma is a group of malignant neoplasms of lymphocytes that progress in the lymphatic system. Generally, lymphomas are categorized into…
Date: 18th January 2021
The Lymphoma Sessions: highlights from iwNHL 2020
This year’s virtual International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlighted key progress in our understanding of various non-Hodgkin lymphoma (NHL)…
Date: 18th November 2020
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is…
Date: 1st October 2020
SOHO 2020: Next questions in hematological malignancies
The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated…
Date: 25th September 2020
Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells
Lymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin…
Date: 10th September 2020
The Myeloma Sessions: Evolving management of myeloma & COVID-19
Patients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high…
Date: 6th August 2020
The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies
A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of…
Date: 31st July 2020
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)…
Date: 3rd July 2020
